MSD fails in SCOTUS bid to revive record $2.5bn verdict
21-01-2021
Australian court issues mixed vaccine patent ruling
15-10-2020
Idenix $2.5bn ruling will impede innovation, says Amgen
04-02-2020
Atmosphere1 / Shutterstock.com
MSD subsidiary Idenix has urged the US Supreme Court to review the overturning of a record $2.5 billion verdict against Gilead Sciences.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
MSD, SCOTUS, patent infringement, Gilead, Idenix, hepatitis C, US District Court for the District of Delaware, Federal Circuit, Merck, subject matter
